FibroGen

FGEN50

Penny Stock

$0.33arrow_drop_up0.71%$0.00

Penny Stock

FGEN50

$0.33

arrow_drop_up0.71%$0.00

Penny Stock

Performance History

Key Stats
Open	$0.37
Prev. Close	$0.36
EPS	-1.23
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$33.60M
PE Ratio	-

	LOW	HIGH
Day Range	0.32	0.38
52 Week Range	0.28	2.93

Ratios

Revenue	-





EPS	-1.23

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About FibroGen (FGEN)

FibroGen Inc (FGEN) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for the treatment of serious and life-threatening conditions. The company is primarily focused on fibrosis and anemia, with its lead product candidate being roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) activity. Roxadustat is currently in Phase 3 clinical development for the treatment of anemia associated with chronic kidney disease (CKD) and myelodysplastic syndromes (MDS), and Phase 2 clinical development for the treatment of chemotherapy-induced anemia.

FibroGen Inc's stock price history has shown significant volatility over the past few years. The stock reached its all-time high of $76.64 in August 2018, but has since experienced a decline. As of [insert date], the stock is trading at $56.23. This represents a [insert percentage] decrease from its all-time high. The stock has a 52-week range of [insert range], indicating the extent of price fluctuations.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO
Headquarters: San Francisco
Employees: 592
Exchange: NASDAQ

Keep an eye on FibroGen

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

Is FibroGen (FGEN) a growth stock?

FibroGen (FGEN) has shown an average price growth of -6.8% over the past three years. It has received a score of 10 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying FibroGen as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is FibroGen (FGEN) stock price performance year to date (YTD)?

As of the latest data, FibroGen (FGEN) has a year-to-date price change of -59.38%. Over the past month, the stock has experienced a price change of -14.58%. Over the last three months, the change has been -10.67%. Over the past six months, the figure is -71.88%. Looking at a longer horizon, the five-year price change stands at -99.08%.

help

What is FibroGen 's (FGEN) price per share?

The current price per share for FibroGen (FGEN) is $0.34. The stock has seen a price change of $0 recently, indicating a 0.72% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for FibroGen (FGEN)?

For FibroGen (FGEN), the 52-week high is $2.93, which is 768.41% from the current price. The 52-week low is $0.29, the current price is 17.15% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is FibroGen (FGEN) a profitable company?

FibroGen (FGEN) has a net income of -$284.23M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 87.24% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -21.56% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 4.99%, providing insight into the company's sales performance and growth. The gross profit is $128.9M. Operating income is noted at -$281.82M. Furthermore, the EBITDA is -$165.84M.

help

What is the market capitalization of FibroGen (FGEN)?

FibroGen (FGEN) has a market capitalization of $33.88M. The average daily trading volume is 0.34, indicating the stock's liquidity and investor engagement.

News

LIVER FIBROSIS

MARKET GROWTH

EMERGING INDUSTRIES

ADVANCED TECHNOLOGIES

Liver Fibrosis Market Is Expected to Reach USD 43.98 Billion By 2030

CATALYST ACCELERATOR OGDEN

DEPARTMENT OF THE AIR FORCE DIGITAL TRANSFORMATION OFFICE

DIGITAL MODERNIZATION

Catalyst Accelerator Ogden Selects 11 Companies for Fall 2024 Cohort in Partnership with the Department of the Air Force Digital Transformation Office

FibroGen Stock Is Surging After The Bell: What's Going On?

HEALTH

CLINICAL STUDY

Jun 3, 2024

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

CLINICAL STUDY

May 23, 2024

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About FibroGen (FGEN)

Keep an eye on FibroGen

Frequently Asked Questions

Is FibroGen (FGEN) a growth stock?

What is FibroGen (FGEN) stock price performance year to date (YTD)?

What is FibroGen 's (FGEN) price per share?

What is the 52-week high and low for FibroGen (FGEN)?

Is FibroGen (FGEN) a profitable company?

What is the market capitalization of FibroGen (FGEN)?

News

Take Your Investments to a Whole New Level